Vera Therapeutics, Inc.
NASDAQVera Therapeutics has passed its Q2 earnings test and the result was ugly — the stock fell nearly 8% on August 10 following the print, and another 4% the day after, leaving it at $30.29 and down 28% over the past month. The options market called it right. Heading into the print, the put/call ratio had jumped from a steady 0.35 through July to 0.63 — nearly 1.8 standard deviations…
Snapshot as of 23 Aug 2026
Vera Therapeutics has passed its Q2 earnings test and the result was ugly — the stock fell nearly 8% on August 10 following the print, and another 4% the day after, leaving it at $30.29 and down 28% over the past…
Vera Therapeutics reports Q2 results on August 13 with the stock under real pressure — down 25% over the past month and trading at $31.58, against a bull consensus that sees fair value more than twice as high. The most…
Vera Therapeutics enters the second week of July with a striking split: five analysts raised price targets on the same day the stock jumped 7%, yet short sellers are sitting on nearly 19% of the float with no sign of…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VERA — free to start on ORTEX.
Sign up for free →Open VERA on ORTEX